Details

Autor(en) / Beteiligte

• Nielsen, Katrine Finderup
• Nielsen, Lise Birk
• Dalby, Tine
• Lomholt, Frederikke Kristensen
• Slotved, Hans-Christian
• Fuursted, Kurt
• Harboe, Zitta Barrella
• Jørgensen, Charlotte Sværke
• Valentiner-Branth, Palle

Titel

Follow-Up Study of Effectiveness of 23-Valent Pneumococcal Polysaccharide Vaccine Against All-Type and Serotype-Specific Invasive Pneumococcal Disease, Denmark

Ist Teil von

• Emerging infectious diseases, 2024-06, Vol.30 (6), p.1164-1172

Ort / Verlag

United States: U.S. National Center for Infectious Diseases

Erscheinungsjahr

2024

Quelle

MEDLINE

Beschreibungen/Notizen

• As a follow-up to a previous study, we investigated vaccine effectiveness (VE) of 23-valent pneumococcal polysaccharide vaccine (PPSV23) against invasive pneumococcal disease (IPD) among 1,254,498 persons >65 years of age as part of a vaccination program in Denmark during April 2020-January 2023. We assessed VE by using a Cox regression model and adjusted for age, sex, and underlying conditions. Using nationwide data, we estimated a VE of PPSV23 against all-type IPD of 32% and against PPSV23-serotype IPD of 41%. Because this follow-up study had more statistical power than the original study, we also estimated VE against IPD caused by PPSV23-serotypes excluding serotype 3; serotype 3; serotype 8; serotype 22F; PPSV23 non-PCV15 serotypes; PPSV23 non-PCV20 serotypes; and IPD over time. Our findings suggest PPSV23 vaccination can protect persons >65 years of age against IPD caused by all serotypes or serotype groupings, except serotype 3.